Anebulo Pharmaceuticals earnings were -$8.5M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest ANEB earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$2.1M, up 28% from last quarter. For the last reported fiscal year 2025 ending Jun 30, 2025, ANEB reported annual earnings of -$8.5M, with 3.5% growth. The next ANEB earnings date is Nov 7, 2025.
Anebulo Pharmaceuticals Earnings Reports & History FAQ
What were Anebulo Pharmaceuticals's earnings last quarter?
On ANEB's earnings call on Invalid Date, Anebulo Pharmaceuticals (NASDAQ: ANEB) reported Q2 2025 earnings per share (EPS) of -$0.05, up 0% year over year. Total ANEB earnings for the quarter were -$2.14 million. In the same quarter last year, Anebulo Pharmaceuticals's earnings per share (EPS) was -$0.05.
When does Anebulo Pharmaceuticals report earnings?
The next ANEB earnings call is Invalid Date. Add ANEB to your watchlist to be reminded of Anebulo Pharmaceuticals's next earnings date.
Is Anebulo Pharmaceuticals profitable or losing money?
As of the last Anebulo Pharmaceuticals earnings report, Anebulo Pharmaceuticals is currently losing money. Anebulo Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$8.48 million, a 3.45% increase year over year.
What was ANEB's earnings growth in the past year?
As of Anebulo Pharmaceuticals's earnings date in Invalid Date, Anebulo Pharmaceuticals's earnings has grown year over year. ANEB earnings in the past year totalled -$8.48 million.
What are Anebulo Pharmaceuticals's earnings expectations?
The current EPS estimate for Anebulo Pharmaceuticals's earnings report in Invalid Date is $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.